{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Symbicort+160%2F4.5+pMDI",
    "query": {
      "intervention": "Symbicort 160/4.5 pMDI"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Symbicort+160%2F4.5+pMDI&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T03:43:01.832Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06473779",
      "title": "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Asthma"
      ],
      "interventions": [
        {
          "name": "Tezepelumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Budesonide/formoterol",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Albuterol/budesonide (AIRSUPRA®)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Mannitol",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Salbutamol",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 326,
      "start_date": "2024-09-30",
      "completion_date": "2027-06-25",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 8,
      "location_summary": "Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Palmdale",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06473779"
    },
    {
      "nct_id": "NCT00419757",
      "title": "An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide/formoterol (SYMBICORT) pMDI",
          "type": "DRUG"
        },
        {
          "name": "Budesonide HFA pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 558,
      "start_date": "2007-01",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-08-27",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 32,
      "location_summary": "Anaheim, California • Chula Vista, California • Fresno, California + 29 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419757"
    },
    {
      "nct_id": "NCT00206167",
      "title": "A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Budesonide/formoterol pMDI",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Turbuhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1600,
      "start_date": "2005-04",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2009-03-27",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 131,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206167"
    },
    {
      "nct_id": "NCT00702325",
      "title": "Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide / formoterol fumarate (SYMBICORT)",
          "type": "DRUG"
        },
        {
          "name": "Budesonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2008-06",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-11-09",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 57,
      "location_summary": "Pell City, Alabama • Bentonville, Arkansas • Hot Springs, Arkansas + 54 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Malvern",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00702325"
    },
    {
      "nct_id": "NCT00867737",
      "title": "Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Advair HFA MDI 115/21",
          "type": "DRUG"
        },
        {
          "name": "Symbicort 160/4.5 pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergy and Asthma Center of El Paso",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-09",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2009-03-24",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00867737"
    },
    {
      "nct_id": "NCT00206154",
      "title": "A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Budesonide/formoterol pMDI",
          "type": "DRUG"
        },
        {
          "name": "Budesonide pMDI",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Turbuhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1500,
      "start_date": "2005-04",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2009-03-27",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 143,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206154"
    },
    {
      "nct_id": "NCT00419744",
      "title": "A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Budesonide/formoterol (SYMBICORT) pMDI",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Turbuhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2007-01",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2010-09-16",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 92,
      "location_summary": "Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419744"
    },
    {
      "nct_id": "NCT01444430",
      "title": "A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "budesonide pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 12460,
      "start_date": "2011-12",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 160,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01444430"
    },
    {
      "nct_id": "NCT01136655",
      "title": "A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "80/2.25 μg Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "80/4.5 μg Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "Foradil Aerolizer 12 μg",
          "type": "DRUG"
        },
        {
          "name": "40 μg budesonide HFA pMDI",
          "type": "DRUG"
        },
        {
          "name": "placebo HFA pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 54,
      "start_date": "2010-09",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-10-31",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 20,
      "location_summary": "Huntington, California • Long Beach, California • Mission Viejo, California + 17 more",
      "locations": [
        {
          "city": "Huntington",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estate",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01136655"
    },
    {
      "nct_id": "NCT02157935",
      "title": "Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD Patients"
      ],
      "interventions": [
        {
          "name": "Symbicort",
          "type": "DRUG"
        },
        {
          "name": "Formoterol turbohaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Symbicort pMDI",
          "type": "OTHER"
        },
        {
          "name": "Placebo for Formoterol Turbohaler",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "40 Years to 95 Years"
      },
      "enrollment_count": 2026,
      "start_date": "2014-06-27",
      "completion_date": "2016-02-08",
      "has_results": true,
      "last_update_posted_date": "2017-11-07",
      "last_synced_at": "2026-09-28T03:43:01.832Z",
      "location_count": 224,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02157935"
    }
  ]
}